CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 63 enrolled
Drug / intervention
TER-101 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04753034
NCT04753034Phase 2Completed
CompareCT.gov

A Multicenter, Randomized, Double-blind, Vehicle-Controlled, Phase 2 Study of TER-101 Topical Ointment to Assess Efficacy and Safety in Subjects With Mild to Moderate Atopic

Teres Bio, Inc.·interventional·Posted Feb 12, 2021·Updated Jul 26, 2022

In Brief

A Phase 2 clinical trial evaluating TER-101 and Vehicle for Atopic Dermatitis. Completed, enrolled 63 participants across 12 sites.

Detailed Summary

This Phase 2 study will assess efficacy, safety, and tolerability of TER-101 ointment and vehicle twice daily for 28 days in adult and adolescent subjects with mild to moderate atopic dermatitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedFeb 12, 2021
Enrollment StartJan 18, 2021
Primary CompletionMay 3, 2021
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 5.4 years ago

Interventions

TER-101drug

Active Comparator

Vehicledrug

Placebo Comparator